Oncolytics Biotech Inc ONCY

Companies now seek to moderate TME to expand PD-(L)1 effect

[Noteable]

October 19, 2022 - "PD-L1 expression, while still an important biomarker, is not the static, “yes/no” predictor of tumor response for which researchers hoped. 

The challenge for PD-1/PD-L1 checkpoint inhibitors is the tumor microenvironment (TME). It is such a complicated mass of cells and proteins that no single therapy is likely to cure all or even many types of cancers in all patients. 

Now companies are pursuing other targets, often as adjuvants to moderate the TME and thus expand the efficacy of anti-PD-1/anti-PD-L1 therapies.

[ONCY's pelareorep is one such target that has already demonstrated that it is able to moderate/remodel the TME to expand the efficacy of anti-PD-(L)1 immune checkpoint inhibitor therapies by also employing innovative predictive biomarkers that are able to identify which patients will positively respond to the pelareorep + ICI immuno-oncology combination before and then throughout the course of treatment ]

https://www.biospace.com/article/beyond-anti-pd-1-pd-li-3-companies-swing-for-the-fences-with-new-targets-/